The Filing Desk

Siga Technologies vs Zevra Therapeutics

Siga Technologies SIGA · Zevra Therapeutics ZVRA · Pharmaceuticals

Zevra Therapeutics reported revenue of $106 million in fiscal 2025, about the same as Siga Technologies' $95 million in fiscal 2025. Siga Technologies' revenue fell 31.8% in its latest year, and Zevra Therapeutics' grew 350.9%. Siga Technologies had an operating margin of 25.1%, against -59.1% at Zevra Therapeutics. Free cash flow was $43 million at Siga Technologies and −$2 million at Zevra Therapeutics.

Side by side

Siga TechnologiesZevra Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$95M$106M
Revenue growth−31.8%350.9%
Revenue growth a year, last 5 years−5.4%51.6%
Gross margin68.6%—
Operating margin25.1%−59.1%
Net margin24.6%78.2%
Free cash flow$43M−$2M
Free cash flow margin45.6%−2.3%
Return on capital34.8%−218.8%
Net debt to EBITDA−6.4x—
Dividends and buybacks$43M$0M
Change in diluted share count−0.1%23.8%
Last close$2.65$9.07
P/E at the last close—7.6×
Insider trades, last 12 months—sold $2.3 million
Piotroski F-score5 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Siga TechnologiesZevra Therapeutics
Operating margin
Percent of revenue
Siga TechnologiesZevra Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Siga TechnologiesZevra Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Siga Technologies and Zevra Therapeutics pages.